Amneal Pharmaceuticals (AMRX) Equity Average (2018 - 2026)

Amneal Pharmaceuticals' Equity Average history runs 9 years deep, the most recent figure standing at -$58.1 million for Q1 2026.

• In Q1 2026, Equity Average rose 51.88% year-over-year to -$58.1 million; the TTM figure through Mar 2026 stood at -$58.1 million (up 51.88% YoY), while the FY2025 annual figure was -$90.2 million, down 101.46% from the prior year.
• Equity Average was -$58.1 million for Q1 2026 at Amneal Pharmaceuticals, up from -$90.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $387.2 million in Q1 2022 to a low of -$122.3 million in Q2 2025.
• Historically, Equity Average has averaged $48.8 million across 5 years, with a median of -$21.8 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Equity Average plunged 453.7% in 2025, then surged 51.88% in 2026.
• A 5-year view of Equity Average shows it stood at $189.1 million in 2022, then slumped by 53.94% to $87.1 million in 2023, then plunged by 216.55% to -$101.5 million in 2024, then increased by 11.0% to -$90.4 million in 2025, then jumped by 35.71% to -$58.1 million in 2026.
• The last three Equity Average figures came in at -$58.1 million (Q1 2026), -$90.4 million (Q4 2025), and -$111.2 million (Q3 2025), per Business Quant data.